Fish Oil: A Latest Hope for Dialysis Patients’ Heart Health
A daily fish oil supplement is showing remarkable promise in reducing the risk of serious cardiovascular complications for individuals undergoing dialysis due to kidney failure. Recent findings from the large-scale, international PISCES trial, led by Monash Health and Monash University in Australia, reveal a significant positive impact on heart health within this vulnerable patient population.
The PISCES Trial: Key Findings
The PISCES trial involved 1,228 participants receiving dialysis at 26 sites across Australia and Canada. The results, presented at the American Society of Nephrology Kidney Week 2025 and published in The New England Journal of Medicine, demonstrated a compelling link between fish oil supplementation and improved cardiovascular outcomes.
Participants who consumed four grams of fish oil daily experienced a 43 percent reduction in major cardiovascular events compared to those receiving a placebo. These events encompassed heart attack, stroke, cardiac death, and vascular-related amputations. The fish oil used in the trial contained the essential omega-3 fatty acids, EPA and DHA.
Why Dialysis Patients Are at Higher Risk
Patients undergoing dialysis face an exceptionally high risk of cardiovascular disease. “Patients on dialysis have extremely high cardiovascular risk, and very few therapies have been shown to reduce that risk,” explains Adjunct Professor Kevan Polkinghorne, a nephrologist at Monash Health. “In a field where many trials have been negative, this is a significant finding.”
Professor Polkinghorne also noted that dialysis patients often exhibit lower levels of EPA and DHA compared to the general population, potentially contributing to the observed benefits of supplementation.
Specificity of the Findings
It’s crucial to understand that these findings are specifically applicable to individuals undergoing haemodialysis for kidney failure. Researchers emphasize that the results should not be extrapolated to healthy individuals or other patient groups. This targeted approach highlights the importance of personalized medicine and tailoring interventions to specific needs.
Future Trends and Research Directions
The success of the PISCES trial is likely to spur further research into the role of omega-3 fatty acids in managing cardiovascular health within the dialysis population. Several key trends are emerging:
- Personalized Omega-3 Dosing: Future studies may explore optimal dosages of EPA and DHA based on individual patient characteristics, such as baseline omega-3 levels and genetic predispositions.
- Combination Therapies: Researchers will likely investigate whether combining fish oil supplementation with other existing cardiovascular therapies can yield synergistic benefits.
- Expanding to Peritoneal Dialysis: While the PISCES trial focused on haemodialysis, future research may assess the efficacy of fish oil in patients undergoing peritoneal dialysis.
- Long-Term Outcomes: Longitudinal studies are needed to evaluate the sustained effects of fish oil supplementation on cardiovascular health and overall survival in dialysis patients.
- Cost-Effectiveness Analysis: As healthcare systems increasingly prioritize value-based care, studies assessing the cost-effectiveness of fish oil supplementation will be crucial for widespread adoption.
The Australasian Kidney Trials Network (AKTN) managed trial coordination, with support from the National Health and Medical Research Council (NHMRC) for the Australian portion of the study. Approximately 200 Australian participants, including 44 from Monash Health, contributed to the trial’s success.
Did you know?
Omega-3 fatty acids are essential fats that the body cannot produce on its own, meaning they must be obtained through diet or supplementation.
FAQ
Q: Is fish oil safe for dialysis patients?
A: The PISCES trial demonstrated that four grams of fish oil daily was well-tolerated by participants undergoing haemodialysis.
Q: Can I take fish oil if I have kidney problems but am not on dialysis?
A: This research specifically applies to those on haemodialysis. Consult your doctor before starting any new supplement regimen if you have kidney issues.
Q: What type of fish oil is best?
A: The PISCES trial used a supplement containing both EPA and DHA. Discuss the best option for you with your healthcare provider.
Q: Will fish oil eliminate my risk of heart problems on dialysis?
A: Fish oil significantly reduces the risk, but it doesn’t eliminate it. It should be considered as part of a comprehensive cardiovascular care plan.
Pro Tip: Talk to your nephrologist about whether fish oil supplementation is appropriate for you, considering your individual health status and medications.
Stay informed about the latest advancements in kidney health and cardiovascular care. Explore more research from Monash University and visit the American Society of Nephrology to learn more.
Do you have questions about fish oil and dialysis? Share your thoughts in the comments below!